NCT06265532

Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect

Name: Clinical Trial NCT06265532
Creator: Hal Chapman
Keywords: Idiopathic Pulmonary Fibrosis, EGCG 300 mg, Phase 1, drug, clinical trial, United States of America

Collagen-targeted PET Imaging for Assessment of EGCG Effect

Hal Chapman·Phase 1·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Idiopathic Pulmonary Fibrosis
Drug/Device/Intervention: EGCG 300 mg
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Hal Chapman
Funder: University of California, San Francisco
Location: Boston, United States of America

Timeline & enrollment

Phase: Phase 1
Start date: Feb 07, 2024
End date: May 31, 2025
Enrollment: 22 participants

Primary outcome

Change in collagen probe uptake over the entire lungs

Summary

The primary purpose of this substudy is to determine if collagen-targeted PET using the type 1 collagen-targeted PET probe, Gallium-68 (68Ga)-labeled collagen binding probe 8 (CBP8) can inform as to drug effect of EGCG and assist in dose selection.

ICD-10 classifications

Other interstitial pulmonary diseases with fibrosisCystic fibrosis with pulmonary manifestationsCystic fibrosisGraphite fibrosis (of lung)Pulmonary heart disease, unspecified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06265532
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06265532 through Pure Global AI's free database. This Phase 1 trial is sponsored by Hal Chapman and is currently Recruiting. The study focuses on Idiopathic Pulmonary Fibrosis. Target enrollment is 22 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.